Epigenomics Joins Forces with hundreds of Organizations to Increase Colorectal Cancer Screening Rates in the United States

DGAP-News: Epigenomics AG / Key word(s): Miscellaneous27.02.2017 / 13:30The issuer is solely responsible for the content of this announcement.---------------------------------------------------------------------------Epigenomics Joins Forces with hundreds of Organizations to IncreaseColorectal Cancer Screening Rates in the United States"80% by 2018" is a shared goal to have 80% of adults aged 50 and olderscreened for colorectal cancer by 2018 - Colorectal cancer screening hasbeen proven to save livesBerlin (Germany) and Germantown, MD (U.S.A.), February 27, 2017 -Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), todayannounced that it has made the pledge to help increase colorectal cancerscreening rates by supporting the 80% by 2018 initiative, led by theAmerican Cancer Society (ACS), the Centers for Disease Control andPrevention (CDC) and the National Colorectal Cancer Roundtable (a coalitionco-founded by ACS and CDC).Colorectal cancer is the nation's second-leading cause of cancer-relateddeaths in the U.S. when men and women are combined; however it is one ofonly a few cancers that can be prevented. Through colorectal cancerscreening, doctors can find and remove hidden growths (called "polyps") inthe colon, before they become cancerous. Removing polyps can preventcancer."80% by 2018" is a National Colorectal Cancer Roundtable (NCCRT) initiativein hundreds of organizations have committed to substantially reducingcolorectal cancer as a major public health problem and are working towardthe shared goal of 80% of adults aged 50 and older being regularly screenedfor colorectal cancer by 2018. Leading public health organizations, such asNCCRT, CDC and the ACS are rallying organizations to embrace this sharedgoal. If we can achieve 80% by 2018, 277,000 cases and 203,000 colorectalcancer deaths would be prevented by 2030."We are excited to join forces with the "80% by 2018"-initiative in thefight against colorectal cancer," said Greg Hamilton, Chief ExecutiveOfficer of Epigenomics AG. "We believe that lowering existing screeninghurdles such as patient preparation or stool handling is key to increasescreening rates in the United States. Epi proColon(R), our novelFDA-approved blood-test for colorectal cancer screening, is a convenientand cost-effective test that has demonstrated high acceptance amongpatients who refuse existing methods. We are committed to provide patientsnationwide with this new disruptive technology, thereby making asignificant contribution to the "80%" goal."Part of the 80% by 2018 goal is to leverage the energy of multiple anddiverse partners to empower communities, patients and providers to increasescreening rates. The 80% by 2018 initiative consists of health careproviders, health systems, communities, businesses, community healthcenters, government, non-profit organizations and patient advocacy groups,among others, who are committed to getting more people screened forcolorectal cancer to prevent more cancers and save lives.For more information about colorectal cancer screening, visitwww.cancer.org/colon or contact the American Cancer Society at1-800-227-2345.  For more information about the 80% by 2018 initiative,visit www.nccrt.org.About Epi proColonEpi proColon is indicated for colorectal cancer screening in average-riskpatients who are unwilling or unable to perform colorectal cancer screeningby colonoscopy and stool-based methods.For patients, the test only requires a simple blood sample drawn as part ofroutine healthcare provider visits. There are no dietary restrictions oralterations in medication required for the test. The sample will beanalyzed at a national or regional diagnostic laboratory.For more information, visit www.epiprocolon.com. About EpigenomicsEpigenomics is a molecular diagnostics company focused on blood-baseddetection of cancers using its proprietary DNA methylation biomarkertechnology. The company develops and commercializes diagnostic productsacross multiple cancer indications with high medical need. Epigenomics'lead product, Epi proColon, is a blood-based screening test for thedetection of colorectal cancer. Epi proColon has received approval from theU.S. Food and Drug Administration (FDA) and is currently marketed in theUnited States, Europe, and China and selected other countries. Epigenomics' second product, Epi proLung(R), is in development as ablood-based test for lung cancer detection.For more information, visit www.epigenomics.com. Contact in the U.S.David BullDirector of MarketingPhone: 240.912.6430David.Bull@Epigenomics.comContact Epigenomics AGPeter VogtVice President Corporate Communication & Investor RelationsEpigenomics AGGeneststraße 510829 BerlinPhone +49 (0) 30 24345 386ir@epigenomics.comEpigenomics legal disclaimerThis communication expressly or implicitly contains certain forward-lookingstatements concerning Epigenomics AG and its business. Such statementsinvolve certain known and unknown risks, uncertainties and other factorswhich could cause the actual results, financial condition, performance orachievements of Epigenomics AG to be materially different from any futureresults, performance or achievements expressed or implied by suchforward-looking statements. Epigenomics AG is providing this communicationas of this date and does not undertake to update any forward-lookingstatements contained herein as a result of new information, future eventsor otherwise.---------------------------------------------------------------------------27.02.2017 Dissemination of a Corporate News, transmitted by DGAP - aservice of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements,Financial/Corporate News and Press Releases.Archive at www.dgap.de---------------------------------------------------------------------------   Language:    English   Company:     Epigenomics AG                Geneststraße 5                10829 Berlin                Germany   Phone:       +49 30 24345-0   Fax:         +49 30 24345-555   E-mail:      ir@epigenomics.com   Internet:    www.epigenomics.com   ISIN:        DE000A11QW50   WKN:         A11QW5   Listed:      Regulated Market in Frankfurt (Prime Standard); Regulated                Unofficial Market in Berlin, Dusseldorf, Munich,                Stuttgart, Tradegate Exchange     End of News    DGAP News Service